

Index

- 11C-PIB, 123
18F-choline, 123
18FDG-PET/CT, 72
18F-DOPA, 123
18F-fluoro-deoxy-glucose, 72
18F-NAF, 123
68Ga-DOTA-PePeptide, 123
68Ga-PSMA, 123
- A**
ABC subtype, 28
Accessibility, 120
Advanced stage Hodgkin lymphoma, 98
Alternative splicing, 51
Anaplastic large cell lymphoma, 2, 18
Ann Arbor staging system, 28
Argentina, 122
Argentine group for the treatment of acute leukemia, 124
Assessment of response, 105
- B**
B-cell development, 5, 6
B-cell lymphoma, 2
Brentuximab vedotin, 100
Burkitt lymphoma, 2, 14
- C**
Cancer personalized profiling, 92
CD47 checkpoint, 104
- Cell free DNA, 91
CHECKMATE-205, 102
Chromatin formation, 48
Chronic inflammation, 33
Circulating tumor DNA, 90
Classic Hodgkin lymphoma, 2
Clinical features, 38
Clinical trials, 124
Clinicopathological features, 62
Combination strategies, 103
Computed tomography, 72
conventional salvage chemotherapies, 100
CPIs, 106
ctDNA technologies, 91
Cyclotron, 123
- D**
Deauville 5-point scale, 72, 88
Deep sequencing, 92
Diagnostic approaches, 126
Differential diagnosis, 31
Diffuse large B-cell lymphoma, 2, 28
Digital PCR, 92
Disease response assessment, 91
DNA damage repair, 50
Duration of therapy, 105
- E**
Early-stage disease, 94
EORTC criteria, 95
Epidemiology, 2, 31

Epstein-Barr virus + T-cell lymphoma, 2
Epstein-Barr virus, 29

Epstein-Barr Virus-Positive Diffuse Large B Cell Lymphoma, 27

Etiology, 2, 61

Evaluation of therapeutic response, 120

F

FDG-avid bone marrow lesions, 86
Follicular Lymphoma, 121, 129
Follow-up evaluations, 131
Future perspectives, 93

G

GATLA, 124
Guidelines, 118

H

H3K36me, 48
Hepatosplenic T-cell lymphoma, 52
Histologic features, 11
Histological subtypes, 62
Histology, 93
Histone H3 lysine 36 methylation, 48
Histone lysine methyltransferase, 47
Histone methyltransferase, 47
Hodgkin lymphoma, 2, 6, 83

I

Immune checkpoint inhibitors, 102
Immunophenotypic features, 11
Incidence, 3
Intermediate-stage disease, 94
International guidelines, 91

International prognostic index, 28

IRF4 rearrangement, 2

J

JAK/STAT, 32, 36
Juvenile myelomonocytic leukemia, 20

K

Karyotype, 32, 33
KEYNOTE-087, 102
Ki-67, 32, 33
Kidneys, 128

L

Lugano classification, 72, 119
Lymphoblastic leukemia/lymphoma, 53
Lymphoblastic lymphoma, 2, 12
Lymphoid malignancy, 47
Lymphoma response to
 immunomodulatory therapy
 criteria, 89
Lymphoma staging and restaging, 119
Lymphomatoid granulomatosis, 33
LYRIC, 89

M

Malignant lymphomas, 60, 71
Mantle Cell Lymphoma, 78, 121
Mature B-cell lymphoma, 53
Metabolic response, 86
Metabolic tumor volume, 73, 90
Methotrexate-associated
 lymphoproliferative disorders, 60

Monomorphic epitheliotropic intestinal T-cell lymphoma, 52
Mucocutaneous ulcer, 34

N

National comprehensive cancer network, 28
National integrated health service, 120
Natural history, 29
Next-generation sequencing, 91
Nivolumab, 89
Nodular lymphocyte predominant Hodgkin lymphoma, 2
Non-Hodgkin lymphoma, 2, 7

O

OII-LPD, 60
Other iatrogenic immunodeficiency-associated lymphoproliferative disorders, 59
Overall management, 83
Overall survival, 73

P

Pathogenesis, 1, 4, 34
Pathological findings, 36
Pathology, 1
Pediatric Lymphoma, 1
Pediatric-type follicular lymphoma, 2
PET/CT, 85, 117
Plasmablastic lymphoma, 33
Positron emission tomography, 72
Primary mediastinal B-cell lymphoma, 76
Prognosis, 67
Prognostic scores, 95
Progression-free survival, 73

Protein structure, 48

Q

Quality controls, 132

R

Radiomics, 71
R-CHOP, 28
Recent progress, 83
Recovery curve, 134
Reed-Steinberg cells, 2, 37
Refractory classical Hodgkin's lymphoma, 100
Relapsed classical Hodgkin's lymphoma, 100
Response assessment, 72
Response-adapted treatment strategies, 88
Restaging, 121
Revised international prognostic index, 28

S

Sample collection and processing, 91
Saudi Arabia, 129
SET domain containing 2, 47
SETD2, 47
Specific considerations, 121
Staging, 120
Standardized uptake value, 72
SUV-related indexes, 132

T

Total lesion glycolysis, 73
Toxicity, 104
Transcriptional regulation, 50
Treatment and outcome, 39

U

- Ukraine, 126
Ukrainian national guidelines, 127
Uruguay, 119
Uruguayan Group of Lymphomas, 120

V

- VDJ profile, 91

W

- World Health Organization, 28

X

- X linked lymphoproliferative syndrome, 7

Y

- Young patients, 131

Z

- Zinc finger MYND-domain containing 11, 51
ZMYND11, 51

Doi: <https://doi.org/10.36255/exon-publications.lymphoma.2021.Index>